Clinical Pearls in Intermediate Stage uHCC Management

Opinion
Video

The panelist discusses, for intermediate-stage unresectable hepatocellular carcinoma (uHCC), key clinical pearls include prioritizing transarterial chemoembolization (TACE) as a first-line therapy, with systemic options for TACE-ineligible patients or progression; consider lenvatinib or atezolizumab plus bevacizumab based on liver function and risk factors. Evaluate treatment success via a radiologic response (mRECIST criteria), AFP levels, and toxicity profiles; modify treatment upon radiologic progression, prohibitive toxicity, or declining performance status.

Video content above is prompted by the following:

  • What remaining clinical pearls can you share regarding systemic therapy treatment approaches for patients with intermediate stage uHCC?
  • How do you evaluate treatment success over time, and what are the key indicators that guide decisions regarding treatment modifications or sequencing?
  • What trials are you anticipating that might impact the first-line treatment of uHCC?
Recent Videos
1 expert is featured in this series.
1 expert is featured in this series.
4 experts are featured in this series.
Related Content